Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.

Dempsey JM, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, Hertz DL.

Pharmacogenomics. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020.

PMID:
31190621
2.

Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.

Pasternak AL, Kidwell KM, Dempsey JM, Gersch CL, Pesch A, Sun Y, Rae JM, Hertz DL, Park JM.

Pharmacogenomics. 2019 Apr;20(6):421-432. doi: 10.2217/pgs-2019-0002. Epub 2019 Apr 15.

PMID:
30983501
3.

Implication of environmental estrogens on breast cancer treatment and progression.

Gonzalez TL, Rae JM, Colacino JA.

Toxicology. 2019 Jun 1;421:41-48. doi: 10.1016/j.tox.2019.03.014. Epub 2019 Mar 30. Review.

PMID:
30940549
4.

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.

Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S.

Clin Breast Cancer. 2019 Aug;19(4):225-235.e2. doi: 10.1016/j.clbc.2019.02.010. Epub 2019 Mar 6.

PMID:
30928413
5.

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.

Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, Hertz DL.

Breast Cancer Res Treat. 2019 Jun;175(2):297-303. doi: 10.1007/s10549-019-05158-3. Epub 2019 Feb 12.

PMID:
30747308
6.
7.

Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma.

Reimers MA, Shango MM, Daignault-Newton S, Dedinsky R, Karsies D, Kraft S, Riddle L, Felton JA, Wen B, Gersch C, Rae JM, Redman BG, Alva AS.

Invest New Drugs. 2019 Apr;37(2):323-330. doi: 10.1007/s10637-018-0692-8. Epub 2018 Nov 5.

PMID:
30393825
8.

Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines.

Gonzalez TL, Moos RK, Gersch CL, Johnson MD, Richardson RJ, Koch HM, Rae JM.

Toxicol Sci. 2018 Jul 1;164(1):50-59. doi: 10.1093/toxsci/kfy063.

9.

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.

Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, Gersch C, Schott AF, Wu YM, Lonigro R, Robinson DR, Chinnaiyan AM, Bischoff FZ, Johnson MD, Park BH, Hayes DF, Rae JM, Tomlins SA.

Cancer Res. 2018 Feb 15;78(4):1110-1122. doi: 10.1158/0008-5472.CAN-17-2686. Epub 2017 Dec 12.

10.

Functional characterization of the G162R and D216H genetic variants of human CYP17A1.

Capper CP, Liu J, McIntosh LR, Larios JM, Johnson MD, Hollenberg PF, Osawa Y, Auchus RJ, Rae JM.

J Steroid Biochem Mol Biol. 2018 Apr;178:159-166. doi: 10.1016/j.jsbmb.2017.12.002. Epub 2017 Dec 9.

11.

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.

Dempsey JM, Xi J, Henry NL, Rae JM, Hertz DL.

Physiol Genomics. 2018 Feb 1;50(2):98-99. doi: 10.1152/physiolgenomics.00085.2017. Epub 2017 Dec 8.

12.

Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy.

Hertz DL, Luzum JA, Pasternak AL, Ward KM, Zhu HJ, Rae JM, Ellingrod VL.

Pharmacogenomics. 2017 Jul 26. doi: 10.2217/pgs-2017-0107. [Epub ahead of print]

PMID:
28745551
13.

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM.

Breast Cancer Res Treat. 2017 Nov;166(1):277-287. doi: 10.1007/s10549-017-4400-8. Epub 2017 Jul 20.

14.

Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.

Miller P, Kidwell KM, Thomas D, Sabel M, Rae JM, Hayes DF, Hudson BI, El-Ashry D, Lippman ME.

Breast Cancer Res Treat. 2017 Nov;166(1):85-94. doi: 10.1007/s10549-017-4366-6. Epub 2017 Jul 17.

PMID:
28717852
15.

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.

Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22.

16.

Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.

Hertz DL, Henry NL, Rae JM.

Pharmacogenomics. 2017 Apr;18(5):481-499. doi: 10.2217/pgs-2016-0205. Epub 2017 Mar 27. Review.

17.

Steroid receptor coactivator-1 can regulate osteoblastogenesis independently of estrogen.

Watters RJ, Hartmaier RJ, Osmanbeyoglu HU, Gillihan RM, Rae JM, Liao L, Chen K, Li W, Lu X, Oesterreich S.

Mol Cell Endocrinol. 2017 Jun 15;448:21-27. doi: 10.1016/j.mce.2017.03.005. Epub 2017 Mar 7.

PMID:
28286232
18.

Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.

McDermott MS, Chumanevich AA, Lim CU, Liang J, Chen M, Altilia S, Oliver D, Rae JM, Shtutman M, Kiaris H, Győrffy B, Roninson IB, Broude EV.

Oncotarget. 2017 Feb 21;8(8):12558-12575. doi: 10.18632/oncotarget.14894.

19.

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Ahern TP, Hertz DL, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP.

Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17. Review.

20.

Individualized Tamoxifen Dose Escalation-Response.

Hertz DL, Rae JM.

Clin Cancer Res. 2016 Dec 15;22(24):6301. No abstract available.

21.

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL.

Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.

22.

The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.

Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng FY.

Nat Commun. 2016 Sep 26;7:12791. doi: 10.1038/ncomms12791.

23.

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.

Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23.

24.

ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.

Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM.

Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19.

25.

One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity.

Hertz DL, Rae JM.

Pharmacogenomics. 2016 Jun;17(8):823-6. doi: 10.2217/pgs-2016-0059. Epub 2016 Jun 1. No abstract available.

26.

Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.

Chan JM, Darke AK, Penney KL, Tangen CM, Goodman PJ, Lee GM, Sun T, Peisch S, Tinianow AM, Rae JM, Klein EA, Thompson IM Jr, Kantoff PW, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1050-1058. doi: 10.1158/1055-9965.EPI-16-0104. Epub 2016 May 6.

27.

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.

Paoletti C, Larios JM, Muñiz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF.

Mol Oncol. 2016 Aug;10(7):1078-85. doi: 10.1016/j.molonc.2016.04.006. Epub 2016 Apr 29.

28.

Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes.

Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, Hayes DF, Merajver SD, Rae JM, Tewari M.

Clin Biochem. 2016 Dec;49(18):1354-1360. doi: 10.1016/j.clinbiochem.2016.03.012. Epub 2016 Apr 27.

PMID:
27129799
29.

The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.

Capper CP, Larios JM, Sikora MJ, Johnson MD, Rae JM.

Breast Cancer Res Treat. 2016 May;157(1):23-30. doi: 10.1007/s10549-016-3774-3. Epub 2016 Apr 15.

PMID:
27083183
30.

Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.

Hertz DL, Rae JM.

Clin Cancer Res. 2016 Jul 1;22(13):3121-3. doi: 10.1158/1078-0432.CCR-16-0370. Epub 2016 Mar 24.

31.

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL.

Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23.

32.

Pharmacogenetic Predictors of Response.

Hertz DL, Rae JM.

Adv Exp Med Biol. 2016;882:191-215. doi: 10.1007/978-3-319-22909-6_8. Review.

PMID:
26987536
33.

The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.

Capper CP, Rae JM, Auchus RJ.

Horm Cancer. 2016 Jun;7(3):149-64. doi: 10.1007/s12672-016-0259-0. Epub 2016 Mar 11. Review.

34.

Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.

Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM.

Br J Clin Pharmacol. 2016 Jun;81(6):1134-41. doi: 10.1111/bcp.12904. Epub 2016 Apr 8.

35.

Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.

Hertz DL, Caram MV, Kidwell KM, Thibert JN, Gersch C, Seewald NJ, Smerage J, Rubenfire M, Henry NL, Cooney KA, Leja M, Griggs JJ, Rae JM.

Pharmacogenomics. 2016 Feb;17(3):231-40. doi: 10.2217/pgs.15.162. Epub 2016 Jan 22.

36.

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Harvey V, Neven P, Arnould L, Maibach R, Price KN, Coates AS, Goldhirsch A, Gelber RD, Pagani O, Viale G, Rae JM, Regan MM; BIG 1-98 Collaborative Group.

Breast Cancer Res Treat. 2015 Dec;154(3):543-55. doi: 10.1007/s10549-015-3634-6. Epub 2015 Nov 21.

37.

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.

Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.

38.

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA).

Clin Cancer Res. 2016 Mar 15;22(6):1395-402. doi: 10.1158/1078-0432.CCR-15-1213. Epub 2015 Oct 13.

39.

Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.

Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM.

Mol Oncol. 2015 Nov;9(9):1868-76. doi: 10.1016/j.molonc.2015.07.002. Epub 2015 Jul 29.

40.

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, Wong HY, Toro PV, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons HA, Dalton WB, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan AM, Schott A, Robinson D, Jacks KS, Lauring J, Hurley PJ, Hayes DF, Rae JM, Park BH.

Clin Cancer Res. 2016 Feb 15;22(4):993-9. doi: 10.1158/1078-0432.CCR-15-0943. Epub 2015 Aug 10.

41.

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM.

Breast Cancer Res Treat. 2015 Jun;151(2):373-84. doi: 10.1007/s10549-015-3378-3. Epub 2015 May 3.

42.

Re: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Rae JM, Leyland-Jones B, Regan M, Thompson AM.

J Natl Cancer Inst. 2015 Mar 26;107(5). pii: djv065. doi: 10.1093/jnci/djv065. Print 2015 May. No abstract available.

PMID:
25814445
43.

Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid.

Yao PL, Ehresman DJ, Rae JM, Chang SC, Frame SR, Butenhoff JL, Kennedy GL, Peters JM.

Toxicology. 2014 Dec 4;326:62-73. doi: 10.1016/j.tox.2014.10.008. Epub 2014 Oct 18.

PMID:
25456267
44.

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.

Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, Hayes DF.

Clin Cancer Res. 2015 Jun 1;21(11):2487-98. doi: 10.1158/1078-0432.CCR-14-1913. Epub 2014 Nov 7.

45.

Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome.

Drews-Elger K, Iorns E, Dias A, Miller P, Ward TM, Dean S, Clarke J, Campion-Flora A, Rodrigues DN, Reis-Filho JS, Rae JM, Thomas D, Berry D, El-Ashry D, Lippman ME.

Breast Cancer Res Treat. 2014 Nov;148(1):41-59. doi: 10.1007/s10549-014-3122-4. Epub 2014 Oct 1.

PMID:
25270120
46.

Response.

Rae JM, Leyland-Jones B, Regan M.

J Natl Cancer Inst. 2014 Apr 3;106(5). pii: dju064. doi: 10.1093/jnci/dju064. No abstract available.

PMID:
24700799
47.

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM.

Nat Genet. 2013 Dec;45(12):1446-51. doi: 10.1038/ng.2823. Epub 2013 Nov 3.

48.

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.

Henry NL, Chan HP, Dantzer J, Goswami CP, Li L, Skaar TC, Rae JM, Desta Z, Khouri N, Pinsky R, Oesterreich S, Zhou C, Hadjiiski L, Philips S, Robarge J, Nguyen AT, Storniolo AM, Flockhart DA, Hayes DF, Helvie MA, Stearns V.

Br J Cancer. 2013 Oct 29;109(9):2331-9. doi: 10.1038/bjc.2013.587. Epub 2013 Oct 1.

49.

Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C.

J Natl Cancer Inst. 2013 Sep 4;105(17):1332-4. doi: 10.1093/jnci/djt204. Epub 2013 Aug 19.

50.

CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.

Rae JM.

Clin Pharmacol Ther. 2013 Aug;94(2):183-5. doi: 10.1038/clpt.2013.102. Review. No abstract available.

Supplemental Content

Support Center